Authors : Dr. Sanchit Bhandari; Dr. Vijay Deepak Verma; Dr. Arushi Goyal

Volume/Issue : Volume 9 - 2024, Issue 9 - September

Google Scholar : https://tinyurl.com/mhkt7t9a

Scribd : https://tinyurl.com/33khukj6

DOI : https://doi.org/10.38124/ijisrt/IJISRT24SEP1247

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Left Ventricular Failure (LVF) is a complex cardiovascular disorder characterized by impaired left ventricular function, leading to significant morbidity and mortality.  Objective: This review aims to provide a comprehensive overview of LVF, encompassing pathophysiology, diagnosis, treatment, and ongoing research.  Methods: A systematic review of existing literature was conducted, incorporating peer-reviewed articles, clinical guidelines, and ongoing research studies.  Results: LVF results from a complex interplay of hemodynamic, neurohormonal, and molecular mechanisms. Accurate diagnosis requires a comprehensive evaluation of clinical presentation, laboratory results, and imaging studies. Treatment strategies focus on lifestyle modifications, pharmacological therapy, and device therapy to improve symptoms, slow disease progression, and reduce hospitalization and mortality.  Recent Advances: Ongoing research has yielded promising results in stem cell therapy, gene therapy, personalized medicine, and novel imaging modalities. Emerging therapies, including angiotensin receptor-neprilysin inhibitors (ARNIs) and sacubitril/valsartan, have demonstrated improved outcomes in heart failure patients.  Future Directions: Artificial intelligence, cardiac tissue engineering, and microRNA therapeutics hold promise for revolutionizing LVF treatment. Ongoing clinical trials and research studies are investigating innovative approaches to improve diagnosis, treatment, and patient outcomes.  Conclusion: LVF remains a significant public health concern, necessitating continued research and innovation. This review highlights the complex pathophysiology, diagnostic approaches, and treatment strategies for LVF, as well as emerging therapies and future directions.  Implications: This review provides a comprehensive resource for clinicians, researchers, and policymakers, highlighting the need for continued research and innovation in LVF management.

Keywords : Left Ventricular Failure, Heart Failure, Pathophysiology, Diagnosis, Treatment, Stem Cell Therapy, Gene Therapy, Personalized Medicine, Artificial Intelligence.

References :

1. Benjamin EJ, et al. (2019). Heart Disease and Stroke Statistics—2019 Update. Circulation, 139(10), e56-e66.
2. Katz AM. (2010). Cardiac Pump Function. In Physiology of the Heart (pp. 147-164). Lippincott Williams & Wilkins.
3. Braunwald E. (2013). Heart Failure. Journal of Clinical Investigation, 123(1), 114-124.
4. Yancy CW, et al. (2017). 2017 ACC/AHA/HFSA Focused Update of the Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 70(6), 776-803.
5. Pfeffer MA, et al. (2015). Left Ventricular Diastolic Dysfunction and Outcome in Heart Failure. New England Journal of Medicine, 373(11), 1053-1062.
6. Bhatia RS, et al. (2018). Coronary Artery Disease and Heart Failure. Journal of Cardiac Failure, 24(12), 851-858.
7. Whelton PK, et al. (2017). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology, 70(19), e127-e248.
8. Lam CS, et al. (2019). Heart Failure with Preserved Ejection Fraction: A Review. Journal of Cardiac Failure, 25(8), 571-583.
9. Braunwald E. (2013). Heart Failure. Journal of Clinical Investigation, 123(1), 114-124.
10. Packer M. (2014). The Neurohormonal Hypothesis: A Paradigm Shift in the Understanding of Heart Failure. Journal of Cardiac Failure, 20(8), 551-559.
11. Katz AM. (2010). Cardiac Pump Function. In Physiology of the Heart (pp. 147-164). Lippincott Williams & Wilkins.
12. Yancy CW, et al. (2017). 2017 ACC/AHA/HFSA Focused Update of the Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 70(6), 776-803.
13. Menasché P, et al. (2018). Stem cell therapy for heart failure: A systematic review and meta-analysis. Journal of the American College of Cardiology, 72(19), 2285-2295.
14. Lalit PA, et al. (2020). Gene editing for cardiovascular diseases. Circulation Research, 126(5), 637-648.
15. Arnett DK, et al. (2019). Genetic risk scores for predicting susceptibility to left ventricular failure. Journal of the American College of Cardiology, 73(11), 1339-1348.
16. Kramer CM, et al. (2019). Cardiac magnetic resonance imaging in heart failure. Journal of Cardiac Failure, 25(8), 585-594.
17. Singh JP, et al. (2020). Device therapy for heart failure. Journal of the American College of Cardiology, 75(14), 1633-1644.
18. McMurray JJV, et al. (2014). Angiotensin-receptor neprilysin inhibition compared with enalapril on the risk of clinical progression of heart failure. Circulation, 130(12), 953-961.
19. Packer M, et al. (2019). Cardiovascular and renal outcomes with empagliflozin in heart failure. New England Journal of Medicine, 381(15), 1471-1481.
20. FDA. (2021). Verquvo (vericiguat) prescribing information.
21. Armstrong PW, et al. (2020). Vericiguat in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 383(12), 1193-1204.
22. Packer M, et al. (2020). Vericiguat for heart failure with reduced ejection fraction. Journal of the American College of Cardiology, 76(11), 1349-1359.
23. Butler J, et al. (2020). Vericiguat: A novel therapeutic agent for heart failure. European Journal of Heart Failure, 22(9), 1513-1523.